This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES USA: Oligonucleotide & Peptide Therapeutics
May 14-17, 2024 | In-Person + Digital
Boston, MA, USAHynes Convention Center

Hao Wu, Ph.D.
Scientist 4, Peptide Therapeutics at Genentech


Dr. Hao Wu is currently Scientist 4 at Genentech, Departments of Early Discovery Biochemistry, Peptide Therapeutics Division. He has been involved in many projects to improve the drug-like properties of peptides, using rational design, structure-guided design, and combinatorial chemistry approach. Before joining Genentech, Dr. Wu had postdoctoral training at The Scripps Research Institute – Florida using peptidomimetics targeting intracellular targets, and obtained his Ph.D. in Department of Chemistry, National University of Singapore, training in organic chemistry, developed small molecule microarray platform for PPI inhibitor discovery.

Agenda Sessions

  • Potency-enhanced Peptidomimetic VHL Ligands with Improved Oral Bioavailability